Sera Prognostics Q1 net loss $12.2M; revenue $38k; PreTRM orders rise

SERA PROGNOSTICS, INC.

2022-Q1 EPS reported -$0.40 revenue$38,000

Revenue of $38k in Q1 2022 vs $13k in Q1 2021; still minimal.
Net loss widened to $12.2M from $6.4M; operating expenses $12.3M vs $6.0M.
Cash and securities total $129.9M as of March 31, 2022.
Simplified PreTRM ordering process; order trends improving into Q2.
Preeclampsia biomarker validation expected mid-2022; PRIME study on track for 2023 interim readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.